FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis-Reference-Cited by-同舟云学术

FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis

Published:2016-06 Issue:6 Volume:17 Page:801-810
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Suker Mustafa,Beumer Berend R,Sadot Eran,Marthey Lysiane,Faris Jason E,Mellon Eric A,El-Rayes Bassel F,Wang-Gillam Andrea,Lacy Jill,Hosein Peter J,Moorcraft Sing Yu,Conroy Thierry,Hohla Florian,Allen Peter,Taieb Julien,Hong Theodore S,Shridhar Ravi,Chau Ian,van Eijck Casper H,Koerkamp Bas Groot

Publisher

Elsevier BV

Subject

Oncology

Reference37 articles.

1. Cancer statistics, 2012;Siegel;CA Cancer J Clin,2012

2. Advanced pancreatic carcinoma: current treatment and future challenges;Stathis;Nat Rev Clin Oncol,2010

3. Meta-analysis of radical resection rates and margin assessment in pancreatic cancer;Chandrasegaram;Br J Surg,2015

4. Palliative resections versus palliative bypass procedures in pancreatic cancer—a systematic review;Gillen;Am J Surg,2012

5. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement;Callery;Ann Surg Oncol,2009

Cited by 746 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting aberrant amino acid metabolism for pancreatic cancer therapy: Opportunities for nanoparticles;Chemical Engineering Journal;2024-10

2. Nab-paclitaxel plus S-1 followed by gemcitabine-oxaliplatin as first-line alternating sequential treatment of pancreatic ductal adenocarcinoma;The Oncologist;2024-09-03

3. Transforming pancreaticobiliary cancer treatment: Exploring the frontiers of adoptive cell therapy and cancer vaccines;Molecular Therapy: Oncology;2024-09

4. Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: The phase 1/randomised phase 2 SCALOP-2 trial;European Journal of Cancer;2024-09

5. Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer;Cancer Cell;2024-09